Innovations in egnite's CardioCare® Platform Enhance Cardiovascular Care Efficiency
On September 8, 2026, egnite, Inc., a company specializing in healthcare AI, announced significant enhancements to its CardioCare platform, a crucial tool for clinicians managing untreated heart disease. The platform, which caters to over 80 cardiovascular programs nationwide, now offers a simplified user interface to facilitate quicker and more efficient access to vital patient data.
The latest update to CardioCare was developed directly from customer feedback, addressing the needs of clinicians in managing patient cases effectively. By organizing patient details by pathology, the platform provides a comprehensive overview of key findings including Electronic Medical Records (EMR), echocardiogram results, and ECG reports all on a single screen. This redesign allows clinicians to quickly glean critical information without having to navigate through multiple records, enhancing their ability to prioritize patient reviews effortlessly. Additionally, the update introduces severity-based patient lists and a customizable homepage titled 'My CardioCare,' which aligns the interface with the clinical workflows of healthcare teams. Events such as new echocardiograms and patient admissions are now automatically highlighted, supporting a streamlined review process.
As Rachel Bates, an interventional cardiology coordinator at Buffalo General Hospital noted, "This is a real step forward for the platform. Everything we rely on is now faster and easier to access. By facilitating smoother access to critical clinical context, it not only helps us prioritize which patient charts we review but also ensures that we are sending the right patients forward for treatment. egnite has consistently taken feedback into account to make the platform more user-friendly."
The importance of these enhancements cannot be understated, especially considering that many patients with cardiovascular issues remain untreated despite being eligible for intervention. A 2023 report by egnite highlighted that the treatment rate for symptomatic severe aortic stenosis stands at only 58%, which indicates that a staggering 42% of patients are not receiving necessary care within a year of their diagnosis. This underscores the urgency for more proactive solutions in managing cardiovascular disease, an area where egnite's CardioCare excels. The platform was designed to address a variety of cardiovascular conditions including Heart Failure, Atrial Fibrillation, Mitral Valve disease, and Tricuspid Valve issues.
The nature of cardiovascular data generation is fast-paced, with an influx of echo findings, lab results, notes, and referrals often existing in disparate systems. CardioCare brings all this information together, applying specialized AHA-ACC clinical logic tailored for cardiovascular disease. This integration allows clinicians to operate from a unified platform that prioritizes clinically relevant data, presented in a way that is actionable and user-friendly.
Kahla Verhoef, Chief Operating Officer at egnite Health, expressed pride in assisting hospital partners in identifying patients needing immediate attention, a task no clinical team could manage effectively without such support. She noted, "This update makes it even easier for hundreds of specialized cardiovascular users on CardioCare. As heart programs expand their range of diseases treated, CardioCare is equipped to help ensure that these patients receive proper attention from the care team along the guideline-directed treatment pathway."
egnite, Inc. continues to position itself as a leader in the cardiovascular intelligence space, utilizing AI and workflow integration to enhance patient management for healthcare systems. Collaborating with top hospitals and life sciences organizations, egnite aims to boost patient identification, accelerate research, and ultimately improve cardiovascular outcomes globally. Headquartered in Aliso Viejo, California, the company remains committed to advancing the standard of patient care in cardiovascular disease, ensuring those in need are not overlooked.
For more insights on egnite and their innovative solutions, visit www.egnitehealth.com. It’s important to note that the CardioCare platform is not intended for diagnosing, curing, mitigating, treating, or preventing cardiovascular diseases.
The latest update to CardioCare was developed directly from customer feedback, addressing the needs of clinicians in managing patient cases effectively. By organizing patient details by pathology, the platform provides a comprehensive overview of key findings including Electronic Medical Records (EMR), echocardiogram results, and ECG reports all on a single screen. This redesign allows clinicians to quickly glean critical information without having to navigate through multiple records, enhancing their ability to prioritize patient reviews effortlessly. Additionally, the update introduces severity-based patient lists and a customizable homepage titled 'My CardioCare,' which aligns the interface with the clinical workflows of healthcare teams. Events such as new echocardiograms and patient admissions are now automatically highlighted, supporting a streamlined review process.
As Rachel Bates, an interventional cardiology coordinator at Buffalo General Hospital noted, "This is a real step forward for the platform. Everything we rely on is now faster and easier to access. By facilitating smoother access to critical clinical context, it not only helps us prioritize which patient charts we review but also ensures that we are sending the right patients forward for treatment. egnite has consistently taken feedback into account to make the platform more user-friendly."
The importance of these enhancements cannot be understated, especially considering that many patients with cardiovascular issues remain untreated despite being eligible for intervention. A 2023 report by egnite highlighted that the treatment rate for symptomatic severe aortic stenosis stands at only 58%, which indicates that a staggering 42% of patients are not receiving necessary care within a year of their diagnosis. This underscores the urgency for more proactive solutions in managing cardiovascular disease, an area where egnite's CardioCare excels. The platform was designed to address a variety of cardiovascular conditions including Heart Failure, Atrial Fibrillation, Mitral Valve disease, and Tricuspid Valve issues.
The nature of cardiovascular data generation is fast-paced, with an influx of echo findings, lab results, notes, and referrals often existing in disparate systems. CardioCare brings all this information together, applying specialized AHA-ACC clinical logic tailored for cardiovascular disease. This integration allows clinicians to operate from a unified platform that prioritizes clinically relevant data, presented in a way that is actionable and user-friendly.
Kahla Verhoef, Chief Operating Officer at egnite Health, expressed pride in assisting hospital partners in identifying patients needing immediate attention, a task no clinical team could manage effectively without such support. She noted, "This update makes it even easier for hundreds of specialized cardiovascular users on CardioCare. As heart programs expand their range of diseases treated, CardioCare is equipped to help ensure that these patients receive proper attention from the care team along the guideline-directed treatment pathway."
egnite, Inc. continues to position itself as a leader in the cardiovascular intelligence space, utilizing AI and workflow integration to enhance patient management for healthcare systems. Collaborating with top hospitals and life sciences organizations, egnite aims to boost patient identification, accelerate research, and ultimately improve cardiovascular outcomes globally. Headquartered in Aliso Viejo, California, the company remains committed to advancing the standard of patient care in cardiovascular disease, ensuring those in need are not overlooked.
For more insights on egnite and their innovative solutions, visit www.egnitehealth.com. It’s important to note that the CardioCare platform is not intended for diagnosing, curing, mitigating, treating, or preventing cardiovascular diseases.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.